A-LENNON DICLOFENAC 25 mg TABLET

Երկիր: Հարավաֆրիկյան Հանրապետություն

Լեզու: անգլերեն

Աղբյուրը: South African Health Products Regulatory Authority (SAHPRA)

Հասանելի է:

Pharmacare Limited û Woodmead

Դոզան:

See ingredients

Դեղագործական ձեւ:

TABLET

Կազմը:

EACH TABLET CONTAINS DICLOFENAC SODIUM 25 mg

Լիազորման կարգավիճակը:

Registered

Հաստատման ամսաթիվը:

1995-05-04

Ապրանքի հատկությունները

_ZA_ALDICLCOMB_9503_00 _
_ _
_Page 1 of 10 _
1.3.1.1
PROFESSIONAL INFORMATION FOR MEDICINES FOR HUMAN USE
SCHEDULING STATUS
S3
PROPRIETARY NAME AND DOSAGE FORM
A-LENNON DICLOFENAC 25 MG (tablet)
A-LENNON DICLOFENAC 50 MG TABLET
A-LENNON DICLOFENAC 100 MG SUPPOSITORY
COMPOSITION
A-LENNON DICLOFENAC 25 mg:
Each film-coated tablet of A-LENNON DICLOFENAC 25 mg contains 25 mg of
diclofenac
sodium
_Excipients: _
Colloidal anhydrous silica, iron oxide yellow (C.I. 77492), lactose
monohydrate, magnesium
stearate, methacrylic acid copolymer, microcrystalline cellulose,
simethicone, sodium lauryl
sulfate, sodium starch glycolate, starch maize, talc, titanium dioxide
(C.I. 77891), triethyl
citrate
Contains sugar: Lactose monohydrate 85 mg
A-LENNON DICLOFENAC 50 mg TABLET:
Each film-coated tablet of A-LENNON DICLOFENAC 50 mg TABLET contains
50 mg of
diclofenac sodium
_ZA_ALDICLCOMB_9503_00 _
_ _
_Page 2 of 10 _
_Excipients: _
Colloidal anhydrous silica, iron oxide red (C.I. 77491), lactose
monohydrate, magnesium
stearate, methacrylic acid copolymer, povidone, simethicone, sodium
bicarbonate, sodium
lauryl sulphate, starch maize, talc, titanium dioxide (C.I. 77891),
triethyl citrate, yellow iron
oxide (C.I. 77492)
Contains sugar: Lactose monohydrate 86 mg
A-LENNON DICLOFENAC 100 mg SUPPOSITORY:
Each suppository of A-LENNON DICLOFENAC 100 mg SUPPOSITORY contains
100 mg of
diclofenac sodium
_Excipient: _
Suppocire
CATEGORY AND CLASS
A 3.1 Antirheumatics (anti-inflammatory agents)
PHARMACOLOGICAL ACTION
PHARMACODYNAMIC PROPERTIES
Diclofenac is a non-steroidal compound with analgesic,
anti-inflammatory, antirheumatic and
antipyretic properties.
PHARMACOKINETIC PROPERTIES
A single 50 mg dose of enteric-coated tablets results in maximum
plasma concentrations of
about 1 500 ng/ml at 1,5 to 2 hours after ingestion.
_ZA_ALDICLCOMB_9503_00 _
_ _
_Page 3 of 10 _
Diclofenac sodium is eliminated principally by metabolism and
subsequently urinary and
biliary excretion of glucuronide and sulphate conjugates of the
metabolites. The principle